External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>YSB specializes in providing digital solutions in China’s outside-of-hospital pharmaceutical circulation market.</li><li>According to Frost &amp; Sullivan (F&amp;S), the Company is the largest digital pharmaceutical platform serving businesses outside of hospitals in China, taking a market share of 21.0% in 2022 in terms of GMV (gross merchandise volume).</li><li>YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

YSB specializes in providing digital solutions in China’s outside-of-hospital pharmaceutical circulation market.According to Frost &amp; Sullivan (F&amp;S), the Company is the largest digital pharmaceutical platform serving businesses outside of hospitals in China, taking a market share of 21.0% in 2022 in terms of GMV (gross merchandise volume).YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

YSB (9885 HK) – Digitalizing Outside-Of-Hospital Pharmaceutical Circulation Market in China

China

YSB Inc. develops a digital pharmaceutical platform in China, connecting pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions. It offers solutions like ClouMinihouse, Cloud consultation SaaS, ClouWiseDoctor, ClouDiagnos, wePharmacy, and YSB eLearn, alongside wholesale and retail of pharmaceutical and healthcare products. The company was founded in 2015 and is headquartered in Guangzhou, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00